EGFR mutations are the most frequent driver mutations in Chinese NSCLC, and a series of clinical studies have suggested that ICIs may have limited efficacy in EGFR-mutant NSCLC.[22,23] Nonetheless, the relationship between EGFR mutation status and PD-L1 expression remains controversial.[16,24] In the current study, 28.5% of patients with PD-L1 expression carried mutated EGFR, whereas patients with wild-type EGFR showed higher positive and high-positive PD-L1 expression rates and higher TMB. This evidence concerns the gene EGFR and non-small cell lung carcinoma.